nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—autistic disorder—Clonidine—glaucoma	0.266	0.61	CpDpCtD
Atomoxetine—attention deficit hyperactivity disorder—Clonidine—glaucoma	0.17	0.39	CpDpCtD
Atomoxetine—Propranolol—Levobunolol—glaucoma	0.0694	0.276	CrCrCtD
Atomoxetine—Propranolol—Carteolol—glaucoma	0.0694	0.276	CrCrCtD
Atomoxetine—Propranolol—Metipranolol—glaucoma	0.0662	0.263	CrCrCtD
Atomoxetine—Propranolol—Betaxolol—glaucoma	0.0463	0.184	CrCrCtD
Atomoxetine—SLC6A2—Clonidine—glaucoma	0.0276	0.164	CbGbCtD
Atomoxetine—CYP2D6—Carteolol—glaucoma	0.0224	0.133	CbGbCtD
Atomoxetine—CYP2D6—Betaxolol—glaucoma	0.0151	0.0898	CbGbCtD
Atomoxetine—CYP2C19—Methazolamide—glaucoma	0.0151	0.0895	CbGbCtD
Atomoxetine—CYP2C19—Timolol—glaucoma	0.0128	0.0761	CbGbCtD
Atomoxetine—CYP2D6—Methazolamide—glaucoma	0.0115	0.0681	CbGbCtD
Atomoxetine—CYP3A4—Pilocarpine—glaucoma	0.0108	0.0641	CbGbCtD
Atomoxetine—CYP2D6—Timolol—glaucoma	0.00974	0.0579	CbGbCtD
Atomoxetine—CYP3A4—Brinzolamide—glaucoma	0.00846	0.0503	CbGbCtD
Atomoxetine—CYP2D6—Clonidine—glaucoma	0.00828	0.0492	CbGbCtD
Atomoxetine—CYP3A4—Dorzolamide—glaucoma	0.00817	0.0486	CbGbCtD
Atomoxetine—CYP3A4—Methazolamide—glaucoma	0.00728	0.0433	CbGbCtD
Atomoxetine—CYP3A4—Acetazolamide—glaucoma	0.00582	0.0346	CbGbCtD
Atomoxetine—CYP3A4—Clonidine—glaucoma	0.00527	0.0313	CbGbCtD
Atomoxetine—Asthenia—Apraclonidine—glaucoma	8.37e-05	0.000721	CcSEcCtD
Atomoxetine—Somnolence—Brinzolamide—glaucoma	8.36e-05	0.00072	CcSEcCtD
Atomoxetine—Vision blurred—Clonidine—glaucoma	8.33e-05	0.000718	CcSEcCtD
Atomoxetine—Decreased appetite—Dorzolamide—glaucoma	8.32e-05	0.000716	CcSEcCtD
Atomoxetine—Erectile dysfunction—Timolol—glaucoma	8.31e-05	0.000716	CcSEcCtD
Atomoxetine—Urticaria—Acetazolamide—glaucoma	8.29e-05	0.000714	CcSEcCtD
Atomoxetine—Tremor—Clonidine—glaucoma	8.29e-05	0.000714	CcSEcCtD
Atomoxetine—Dyspepsia—Brinzolamide—glaucoma	8.28e-05	0.000713	CcSEcCtD
Atomoxetine—Pruritus—Apraclonidine—glaucoma	8.25e-05	0.000711	CcSEcCtD
Atomoxetine—Body temperature increased—Acetazolamide—glaucoma	8.25e-05	0.000711	CcSEcCtD
Atomoxetine—Fatigue—Dorzolamide—glaucoma	8.25e-05	0.00071	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Pilocarpine—glaucoma	8.23e-05	0.000709	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Travoprost—glaucoma	8.22e-05	0.000708	CcSEcCtD
Atomoxetine—Fatigue—Travoprost—glaucoma	8.21e-05	0.000707	CcSEcCtD
Atomoxetine—Cardiac disorder—Betaxolol—glaucoma	8.21e-05	0.000707	CcSEcCtD
Atomoxetine—Flushing—Betaxolol—glaucoma	8.21e-05	0.000707	CcSEcCtD
Atomoxetine—Pain—Dorzolamide—glaucoma	8.18e-05	0.000705	CcSEcCtD
Atomoxetine—Insomnia—Pilocarpine—glaucoma	8.17e-05	0.000704	CcSEcCtD
Atomoxetine—Decreased appetite—Brinzolamide—glaucoma	8.17e-05	0.000704	CcSEcCtD
Atomoxetine—Weight decreased—Timolol—glaucoma	8.17e-05	0.000704	CcSEcCtD
Atomoxetine—Pain—Travoprost—glaucoma	8.14e-05	0.000702	CcSEcCtD
Atomoxetine—Constipation—Travoprost—glaucoma	8.14e-05	0.000702	CcSEcCtD
Atomoxetine—Agitation—Clonidine—glaucoma	8.13e-05	0.0007	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Brinzolamide—glaucoma	8.12e-05	0.000699	CcSEcCtD
Atomoxetine—Paraesthesia—Pilocarpine—glaucoma	8.12e-05	0.000699	CcSEcCtD
Atomoxetine—Asthenia—Bimatoprost—glaucoma	8.12e-05	0.000699	CcSEcCtD
Atomoxetine—Fatigue—Brinzolamide—glaucoma	8.11e-05	0.000698	CcSEcCtD
Atomoxetine—Pain—Brinzolamide—glaucoma	8.04e-05	0.000693	CcSEcCtD
Atomoxetine—Somnolence—Pilocarpine—glaucoma	8.04e-05	0.000692	CcSEcCtD
Atomoxetine—Depression—Timolol—glaucoma	8.03e-05	0.000691	CcSEcCtD
Atomoxetine—Angiopathy—Betaxolol—glaucoma	8.02e-05	0.000691	CcSEcCtD
Atomoxetine—Pruritus—Bimatoprost—glaucoma	8e-05	0.000689	CcSEcCtD
Atomoxetine—Diarrhoea—Apraclonidine—glaucoma	7.98e-05	0.000688	CcSEcCtD
Atomoxetine—Mediastinal disorder—Betaxolol—glaucoma	7.97e-05	0.000687	CcSEcCtD
Atomoxetine—Dyspepsia—Pilocarpine—glaucoma	7.96e-05	0.000685	CcSEcCtD
Atomoxetine—Chills—Betaxolol—glaucoma	7.94e-05	0.000684	CcSEcCtD
Atomoxetine—Syncope—Clonidine—glaucoma	7.93e-05	0.000683	CcSEcCtD
Atomoxetine—Feeling abnormal—Dorzolamide—glaucoma	7.88e-05	0.000679	CcSEcCtD
Atomoxetine—Decreased appetite—Pilocarpine—glaucoma	7.86e-05	0.000677	CcSEcCtD
Atomoxetine—Feeling abnormal—Travoprost—glaucoma	7.85e-05	0.000676	CcSEcCtD
Atomoxetine—Conjunctivitis—Timolol—glaucoma	7.82e-05	0.000674	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Dorzolamide—glaucoma	7.82e-05	0.000674	CcSEcCtD
Atomoxetine—Palpitations—Clonidine—glaucoma	7.82e-05	0.000673	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Pilocarpine—glaucoma	7.8e-05	0.000672	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Travoprost—glaucoma	7.79e-05	0.000671	CcSEcCtD
Atomoxetine—Loss of consciousness—Clonidine—glaucoma	7.77e-05	0.00067	CcSEcCtD
Atomoxetine—Feeling abnormal—Brinzolamide—glaucoma	7.75e-05	0.000668	CcSEcCtD
Atomoxetine—Mental disorder—Betaxolol—glaucoma	7.75e-05	0.000668	CcSEcCtD
Atomoxetine—Constipation—Pilocarpine—glaucoma	7.73e-05	0.000666	CcSEcCtD
Atomoxetine—Pain—Pilocarpine—glaucoma	7.73e-05	0.000666	CcSEcCtD
Atomoxetine—Cough—Clonidine—glaucoma	7.72e-05	0.000665	CcSEcCtD
Atomoxetine—Dizziness—Apraclonidine—glaucoma	7.71e-05	0.000665	CcSEcCtD
Atomoxetine—Malnutrition—Betaxolol—glaucoma	7.7e-05	0.000663	CcSEcCtD
Atomoxetine—Urticaria—Dorzolamide—glaucoma	7.6e-05	0.000655	CcSEcCtD
Atomoxetine—Abdominal pain—Dorzolamide—glaucoma	7.56e-05	0.000651	CcSEcCtD
Atomoxetine—Body temperature increased—Dorzolamide—glaucoma	7.56e-05	0.000651	CcSEcCtD
Atomoxetine—Tension—Betaxolol—glaucoma	7.56e-05	0.000651	CcSEcCtD
Atomoxetine—Sinusitis—Timolol—glaucoma	7.55e-05	0.000651	CcSEcCtD
Atomoxetine—Dysgeusia—Betaxolol—glaucoma	7.54e-05	0.00065	CcSEcCtD
Atomoxetine—Chest pain—Clonidine—glaucoma	7.53e-05	0.000649	CcSEcCtD
Atomoxetine—Arthralgia—Clonidine—glaucoma	7.53e-05	0.000649	CcSEcCtD
Atomoxetine—Abdominal pain—Travoprost—glaucoma	7.53e-05	0.000649	CcSEcCtD
Atomoxetine—Anxiety—Clonidine—glaucoma	7.5e-05	0.000646	CcSEcCtD
Atomoxetine—Asthenia—Acetazolamide—glaucoma	7.49e-05	0.000645	CcSEcCtD
Atomoxetine—Dizziness—Bimatoprost—glaucoma	7.48e-05	0.000644	CcSEcCtD
Atomoxetine—Nervousness—Betaxolol—glaucoma	7.48e-05	0.000644	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	7.48e-05	0.000644	CcSEcCtD
Atomoxetine—Urticaria—Brinzolamide—glaucoma	7.47e-05	0.000644	CcSEcCtD
Atomoxetine—Feeling abnormal—Pilocarpine—glaucoma	7.45e-05	0.000642	CcSEcCtD
Atomoxetine—Vomiting—Apraclonidine—glaucoma	7.42e-05	0.000639	CcSEcCtD
Atomoxetine—Muscle spasms—Betaxolol—glaucoma	7.4e-05	0.000638	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Pilocarpine—glaucoma	7.39e-05	0.000637	CcSEcCtD
Atomoxetine—Dry mouth—Clonidine—glaucoma	7.36e-05	0.000634	CcSEcCtD
Atomoxetine—Dermatitis—Apraclonidine—glaucoma	7.35e-05	0.000633	CcSEcCtD
Atomoxetine—Headache—Apraclonidine—glaucoma	7.31e-05	0.00063	CcSEcCtD
Atomoxetine—Vision blurred—Betaxolol—glaucoma	7.26e-05	0.000625	CcSEcCtD
Atomoxetine—Tremor—Betaxolol—glaucoma	7.21e-05	0.000621	CcSEcCtD
Atomoxetine—Hallucination—Timolol—glaucoma	7.19e-05	0.000619	CcSEcCtD
Atomoxetine—Asthenia—Brimonidine—glaucoma	7.19e-05	0.000619	CcSEcCtD
Atomoxetine—Infection—Clonidine—glaucoma	7.17e-05	0.000618	CcSEcCtD
Atomoxetine—Abdominal pain—Pilocarpine—glaucoma	7.15e-05	0.000616	CcSEcCtD
Atomoxetine—Body temperature increased—Pilocarpine—glaucoma	7.15e-05	0.000616	CcSEcCtD
Atomoxetine—Diarrhoea—Acetazolamide—glaucoma	7.14e-05	0.000615	CcSEcCtD
Atomoxetine—Rash—Bimatoprost—glaucoma	7.13e-05	0.000614	CcSEcCtD
Atomoxetine—Dermatitis—Bimatoprost—glaucoma	7.13e-05	0.000614	CcSEcCtD
Atomoxetine—Shock—Clonidine—glaucoma	7.1e-05	0.000612	CcSEcCtD
Atomoxetine—Pruritus—Brimonidine—glaucoma	7.09e-05	0.000611	CcSEcCtD
Atomoxetine—Headache—Bimatoprost—glaucoma	7.09e-05	0.00061	CcSEcCtD
Atomoxetine—Nervous system disorder—Clonidine—glaucoma	7.08e-05	0.00061	CcSEcCtD
Atomoxetine—Tachycardia—Clonidine—glaucoma	7.04e-05	0.000607	CcSEcCtD
Atomoxetine—Skin disorder—Clonidine—glaucoma	7.01e-05	0.000604	CcSEcCtD
Atomoxetine—Hyperhidrosis—Clonidine—glaucoma	6.98e-05	0.000601	CcSEcCtD
Atomoxetine—Nausea—Apraclonidine—glaucoma	6.93e-05	0.000597	CcSEcCtD
Atomoxetine—Vertigo—Betaxolol—glaucoma	6.92e-05	0.000596	CcSEcCtD
Atomoxetine—Syncope—Betaxolol—glaucoma	6.9e-05	0.000595	CcSEcCtD
Atomoxetine—Dizziness—Acetazolamide—glaucoma	6.9e-05	0.000595	CcSEcCtD
Atomoxetine—Anorexia—Clonidine—glaucoma	6.88e-05	0.000593	CcSEcCtD
Atomoxetine—Asthenia—Dorzolamide—glaucoma	6.86e-05	0.000591	CcSEcCtD
Atomoxetine—Asthenia—Travoprost—glaucoma	6.83e-05	0.000589	CcSEcCtD
Atomoxetine—Palpitations—Betaxolol—glaucoma	6.8e-05	0.000586	CcSEcCtD
Atomoxetine—Pruritus—Dorzolamide—glaucoma	6.77e-05	0.000583	CcSEcCtD
Atomoxetine—Loss of consciousness—Betaxolol—glaucoma	6.77e-05	0.000583	CcSEcCtD
Atomoxetine—Asthenia—Brinzolamide—glaucoma	6.75e-05	0.000581	CcSEcCtD
Atomoxetine—Pruritus—Travoprost—glaucoma	6.74e-05	0.000581	CcSEcCtD
Atomoxetine—Cough—Betaxolol—glaucoma	6.72e-05	0.000579	CcSEcCtD
Atomoxetine—Nausea—Bimatoprost—glaucoma	6.72e-05	0.000579	CcSEcCtD
Atomoxetine—Cardiac disorder—Timolol—glaucoma	6.71e-05	0.000578	CcSEcCtD
Atomoxetine—Pruritus—Brinzolamide—glaucoma	6.65e-05	0.000573	CcSEcCtD
Atomoxetine—Vomiting—Acetazolamide—glaucoma	6.64e-05	0.000572	CcSEcCtD
Atomoxetine—Dizziness—Brimonidine—glaucoma	6.62e-05	0.000571	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Clonidine—glaucoma	6.58e-05	0.000567	CcSEcCtD
Atomoxetine—Angiopathy—Timolol—glaucoma	6.56e-05	0.000565	CcSEcCtD
Atomoxetine—Chest pain—Betaxolol—glaucoma	6.56e-05	0.000565	CcSEcCtD
Atomoxetine—Myalgia—Betaxolol—glaucoma	6.56e-05	0.000565	CcSEcCtD
Atomoxetine—Arthralgia—Betaxolol—glaucoma	6.56e-05	0.000565	CcSEcCtD
Atomoxetine—Diarrhoea—Dorzolamide—glaucoma	6.54e-05	0.000564	CcSEcCtD
Atomoxetine—Headache—Acetazolamide—glaucoma	6.54e-05	0.000563	CcSEcCtD
Atomoxetine—Anxiety—Betaxolol—glaucoma	6.53e-05	0.000563	CcSEcCtD
Atomoxetine—Insomnia—Clonidine—glaucoma	6.53e-05	0.000562	CcSEcCtD
Atomoxetine—Diarrhoea—Travoprost—glaucoma	6.52e-05	0.000561	CcSEcCtD
Atomoxetine—Mediastinal disorder—Timolol—glaucoma	6.51e-05	0.000561	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	6.51e-05	0.000561	CcSEcCtD
Atomoxetine—Asthenia—Pilocarpine—glaucoma	6.48e-05	0.000559	CcSEcCtD
Atomoxetine—Paraesthesia—Clonidine—glaucoma	6.48e-05	0.000558	CcSEcCtD
Atomoxetine—Diarrhoea—Brinzolamide—glaucoma	6.43e-05	0.000554	CcSEcCtD
Atomoxetine—Somnolence—Clonidine—glaucoma	6.42e-05	0.000553	CcSEcCtD
Atomoxetine—Dry mouth—Betaxolol—glaucoma	6.41e-05	0.000552	CcSEcCtD
Atomoxetine—Pruritus—Pilocarpine—glaucoma	6.39e-05	0.000551	CcSEcCtD
Atomoxetine—Mental disorder—Timolol—glaucoma	6.33e-05	0.000545	CcSEcCtD
Atomoxetine—Dizziness—Dorzolamide—glaucoma	6.33e-05	0.000545	CcSEcCtD
Atomoxetine—Rash—Brimonidine—glaucoma	6.32e-05	0.000544	CcSEcCtD
Atomoxetine—Dermatitis—Brimonidine—glaucoma	6.31e-05	0.000544	CcSEcCtD
Atomoxetine—Dizziness—Travoprost—glaucoma	6.3e-05	0.000543	CcSEcCtD
Atomoxetine—Malnutrition—Timolol—glaucoma	6.29e-05	0.000542	CcSEcCtD
Atomoxetine—Headache—Brimonidine—glaucoma	6.27e-05	0.000541	CcSEcCtD
Atomoxetine—Decreased appetite—Clonidine—glaucoma	6.27e-05	0.000541	CcSEcCtD
Atomoxetine—Infection—Betaxolol—glaucoma	6.24e-05	0.000538	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Clonidine—glaucoma	6.23e-05	0.000537	CcSEcCtD
Atomoxetine—Fatigue—Clonidine—glaucoma	6.22e-05	0.000536	CcSEcCtD
Atomoxetine—Dizziness—Brinzolamide—glaucoma	6.22e-05	0.000536	CcSEcCtD
Atomoxetine—Nausea—Acetazolamide—glaucoma	6.2e-05	0.000534	CcSEcCtD
Atomoxetine—Diarrhoea—Pilocarpine—glaucoma	6.18e-05	0.000533	CcSEcCtD
Atomoxetine—Shock—Betaxolol—glaucoma	6.18e-05	0.000533	CcSEcCtD
Atomoxetine—Tension—Timolol—glaucoma	6.17e-05	0.000532	CcSEcCtD
Atomoxetine—Pain—Clonidine—glaucoma	6.17e-05	0.000532	CcSEcCtD
Atomoxetine—Constipation—Clonidine—glaucoma	6.17e-05	0.000532	CcSEcCtD
Atomoxetine—Nervous system disorder—Betaxolol—glaucoma	6.16e-05	0.000531	CcSEcCtD
Atomoxetine—Dysgeusia—Timolol—glaucoma	6.16e-05	0.000531	CcSEcCtD
Atomoxetine—Tachycardia—Betaxolol—glaucoma	6.13e-05	0.000528	CcSEcCtD
Atomoxetine—Nervousness—Timolol—glaucoma	6.11e-05	0.000526	CcSEcCtD
Atomoxetine—Skin disorder—Betaxolol—glaucoma	6.1e-05	0.000526	CcSEcCtD
Atomoxetine—Vomiting—Dorzolamide—glaucoma	6.08e-05	0.000524	CcSEcCtD
Atomoxetine—Hyperhidrosis—Betaxolol—glaucoma	6.07e-05	0.000523	CcSEcCtD
Atomoxetine—Rash—Dorzolamide—glaucoma	6.03e-05	0.00052	CcSEcCtD
Atomoxetine—Dermatitis—Dorzolamide—glaucoma	6.03e-05	0.000519	CcSEcCtD
Atomoxetine—Rash—Travoprost—glaucoma	6.01e-05	0.000517	CcSEcCtD
Atomoxetine—Dermatitis—Travoprost—glaucoma	6e-05	0.000517	CcSEcCtD
Atomoxetine—Headache—Dorzolamide—glaucoma	5.99e-05	0.000516	CcSEcCtD
Atomoxetine—Anorexia—Betaxolol—glaucoma	5.99e-05	0.000516	CcSEcCtD
Atomoxetine—Vomiting—Brinzolamide—glaucoma	5.98e-05	0.000515	CcSEcCtD
Atomoxetine—Dizziness—Pilocarpine—glaucoma	5.98e-05	0.000515	CcSEcCtD
Atomoxetine—Headache—Travoprost—glaucoma	5.97e-05	0.000514	CcSEcCtD
Atomoxetine—Nausea—Brimonidine—glaucoma	5.95e-05	0.000513	CcSEcCtD
Atomoxetine—Feeling abnormal—Clonidine—glaucoma	5.95e-05	0.000512	CcSEcCtD
Atomoxetine—Rash—Brinzolamide—glaucoma	5.93e-05	0.000511	CcSEcCtD
Atomoxetine—Vision blurred—Timolol—glaucoma	5.93e-05	0.000511	CcSEcCtD
Atomoxetine—Dermatitis—Brinzolamide—glaucoma	5.92e-05	0.00051	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Clonidine—glaucoma	5.9e-05	0.000508	CcSEcCtD
Atomoxetine—Headache—Brinzolamide—glaucoma	5.89e-05	0.000508	CcSEcCtD
Atomoxetine—Vomiting—Pilocarpine—glaucoma	5.75e-05	0.000495	CcSEcCtD
Atomoxetine—Urticaria—Clonidine—glaucoma	5.73e-05	0.000494	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Betaxolol—glaucoma	5.73e-05	0.000493	CcSEcCtD
Atomoxetine—Abdominal pain—Clonidine—glaucoma	5.71e-05	0.000492	CcSEcCtD
Atomoxetine—Body temperature increased—Clonidine—glaucoma	5.71e-05	0.000492	CcSEcCtD
Atomoxetine—Rash—Pilocarpine—glaucoma	5.7e-05	0.000491	CcSEcCtD
Atomoxetine—Dermatitis—Pilocarpine—glaucoma	5.69e-05	0.000491	CcSEcCtD
Atomoxetine—Insomnia—Betaxolol—glaucoma	5.68e-05	0.00049	CcSEcCtD
Atomoxetine—Nausea—Dorzolamide—glaucoma	5.68e-05	0.000489	CcSEcCtD
Atomoxetine—Headache—Pilocarpine—glaucoma	5.66e-05	0.000488	CcSEcCtD
Atomoxetine—Nausea—Travoprost—glaucoma	5.66e-05	0.000487	CcSEcCtD
Atomoxetine—Vertigo—Timolol—glaucoma	5.65e-05	0.000487	CcSEcCtD
Atomoxetine—Paraesthesia—Betaxolol—glaucoma	5.64e-05	0.000486	CcSEcCtD
Atomoxetine—Syncope—Timolol—glaucoma	5.64e-05	0.000486	CcSEcCtD
Atomoxetine—Nausea—Brinzolamide—glaucoma	5.59e-05	0.000481	CcSEcCtD
Atomoxetine—Palpitations—Timolol—glaucoma	5.56e-05	0.000479	CcSEcCtD
Atomoxetine—Dyspepsia—Betaxolol—glaucoma	5.53e-05	0.000477	CcSEcCtD
Atomoxetine—Loss of consciousness—Timolol—glaucoma	5.53e-05	0.000476	CcSEcCtD
Atomoxetine—Cough—Timolol—glaucoma	5.49e-05	0.000473	CcSEcCtD
Atomoxetine—Decreased appetite—Betaxolol—glaucoma	5.46e-05	0.000471	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Betaxolol—glaucoma	5.43e-05	0.000467	CcSEcCtD
Atomoxetine—Fatigue—Betaxolol—glaucoma	5.42e-05	0.000467	CcSEcCtD
Atomoxetine—Pain—Betaxolol—glaucoma	5.37e-05	0.000463	CcSEcCtD
Atomoxetine—Constipation—Betaxolol—glaucoma	5.37e-05	0.000463	CcSEcCtD
Atomoxetine—Nausea—Pilocarpine—glaucoma	5.37e-05	0.000463	CcSEcCtD
Atomoxetine—Myalgia—Timolol—glaucoma	5.36e-05	0.000461	CcSEcCtD
Atomoxetine—Chest pain—Timolol—glaucoma	5.36e-05	0.000461	CcSEcCtD
Atomoxetine—Arthralgia—Timolol—glaucoma	5.36e-05	0.000461	CcSEcCtD
Atomoxetine—Anxiety—Timolol—glaucoma	5.34e-05	0.00046	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	5.32e-05	0.000458	CcSEcCtD
Atomoxetine—Dry mouth—Timolol—glaucoma	5.24e-05	0.000451	CcSEcCtD
Atomoxetine—Asthenia—Clonidine—glaucoma	5.18e-05	0.000446	CcSEcCtD
Atomoxetine—Feeling abnormal—Betaxolol—glaucoma	5.18e-05	0.000446	CcSEcCtD
Atomoxetine—Pruritus—Clonidine—glaucoma	5.11e-05	0.00044	CcSEcCtD
Atomoxetine—Infection—Timolol—glaucoma	5.1e-05	0.000439	CcSEcCtD
Atomoxetine—Shock—Timolol—glaucoma	5.05e-05	0.000435	CcSEcCtD
Atomoxetine—Nervous system disorder—Timolol—glaucoma	5.03e-05	0.000434	CcSEcCtD
Atomoxetine—Urticaria—Betaxolol—glaucoma	4.99e-05	0.00043	CcSEcCtD
Atomoxetine—Skin disorder—Timolol—glaucoma	4.99e-05	0.00043	CcSEcCtD
Atomoxetine—Body temperature increased—Betaxolol—glaucoma	4.97e-05	0.000428	CcSEcCtD
Atomoxetine—Hyperhidrosis—Timolol—glaucoma	4.96e-05	0.000428	CcSEcCtD
Atomoxetine—Diarrhoea—Clonidine—glaucoma	4.94e-05	0.000425	CcSEcCtD
Atomoxetine—Anorexia—Timolol—glaucoma	4.89e-05	0.000422	CcSEcCtD
Atomoxetine—Dizziness—Clonidine—glaucoma	4.77e-05	0.000411	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Timolol—glaucoma	4.68e-05	0.000403	CcSEcCtD
Atomoxetine—Insomnia—Timolol—glaucoma	4.64e-05	0.0004	CcSEcCtD
Atomoxetine—Paraesthesia—Timolol—glaucoma	4.61e-05	0.000397	CcSEcCtD
Atomoxetine—Vomiting—Clonidine—glaucoma	4.59e-05	0.000395	CcSEcCtD
Atomoxetine—Somnolence—Timolol—glaucoma	4.56e-05	0.000393	CcSEcCtD
Atomoxetine—Rash—Clonidine—glaucoma	4.55e-05	0.000392	CcSEcCtD
Atomoxetine—Dermatitis—Clonidine—glaucoma	4.55e-05	0.000392	CcSEcCtD
Atomoxetine—Headache—Clonidine—glaucoma	4.52e-05	0.00039	CcSEcCtD
Atomoxetine—Dyspepsia—Timolol—glaucoma	4.52e-05	0.000389	CcSEcCtD
Atomoxetine—Asthenia—Betaxolol—glaucoma	4.51e-05	0.000388	CcSEcCtD
Atomoxetine—Decreased appetite—Timolol—glaucoma	4.46e-05	0.000384	CcSEcCtD
Atomoxetine—Pruritus—Betaxolol—glaucoma	4.45e-05	0.000383	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Timolol—glaucoma	4.43e-05	0.000382	CcSEcCtD
Atomoxetine—Fatigue—Timolol—glaucoma	4.43e-05	0.000381	CcSEcCtD
Atomoxetine—Pain—Timolol—glaucoma	4.39e-05	0.000378	CcSEcCtD
Atomoxetine—Diarrhoea—Betaxolol—glaucoma	4.3e-05	0.00037	CcSEcCtD
Atomoxetine—Nausea—Clonidine—glaucoma	4.29e-05	0.000369	CcSEcCtD
Atomoxetine—Feeling abnormal—Timolol—glaucoma	4.23e-05	0.000364	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Timolol—glaucoma	4.2e-05	0.000362	CcSEcCtD
Atomoxetine—Dizziness—Betaxolol—glaucoma	4.16e-05	0.000358	CcSEcCtD
Atomoxetine—Urticaria—Timolol—glaucoma	4.08e-05	0.000351	CcSEcCtD
Atomoxetine—Abdominal pain—Timolol—glaucoma	4.06e-05	0.00035	CcSEcCtD
Atomoxetine—Body temperature increased—Timolol—glaucoma	4.06e-05	0.00035	CcSEcCtD
Atomoxetine—Vomiting—Betaxolol—glaucoma	4e-05	0.000344	CcSEcCtD
Atomoxetine—Rash—Betaxolol—glaucoma	3.96e-05	0.000341	CcSEcCtD
Atomoxetine—Dermatitis—Betaxolol—glaucoma	3.96e-05	0.000341	CcSEcCtD
Atomoxetine—Headache—Betaxolol—glaucoma	3.94e-05	0.000339	CcSEcCtD
Atomoxetine—Nausea—Betaxolol—glaucoma	3.73e-05	0.000322	CcSEcCtD
Atomoxetine—Asthenia—Timolol—glaucoma	3.68e-05	0.000317	CcSEcCtD
Atomoxetine—Pruritus—Timolol—glaucoma	3.63e-05	0.000313	CcSEcCtD
Atomoxetine—Diarrhoea—Timolol—glaucoma	3.51e-05	0.000303	CcSEcCtD
Atomoxetine—Dizziness—Timolol—glaucoma	3.39e-05	0.000292	CcSEcCtD
Atomoxetine—Vomiting—Timolol—glaucoma	3.26e-05	0.000281	CcSEcCtD
Atomoxetine—Rash—Timolol—glaucoma	3.24e-05	0.000279	CcSEcCtD
Atomoxetine—Dermatitis—Timolol—glaucoma	3.23e-05	0.000279	CcSEcCtD
Atomoxetine—Headache—Timolol—glaucoma	3.22e-05	0.000277	CcSEcCtD
Atomoxetine—Nausea—Timolol—glaucoma	3.05e-05	0.000263	CcSEcCtD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	2.76e-05	0.000986	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—PTGFR—glaucoma	2.76e-05	0.000985	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—glaucoma	2.75e-05	0.000982	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—SLC6A1—glaucoma	2.71e-05	0.000968	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—SMO—glaucoma	2.71e-05	0.000967	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	2.71e-05	0.000965	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—OPN4—glaucoma	2.66e-05	0.00095	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—PTGFR—glaucoma	2.64e-05	0.000942	CbGpPWpGaD
Atomoxetine—CYP2C19—Biological oxidations—CYP1B1—glaucoma	2.62e-05	0.000936	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—LRP12—glaucoma	2.61e-05	0.000932	CbGpPWpGaD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—glaucoma	2.59e-05	0.000926	CbGpPWpGaD
Atomoxetine—CYP2C19—Metapathway biotransformation—CYP1B1—glaucoma	2.59e-05	0.000923	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—OPN4—glaucoma	2.46e-05	0.000877	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CTSA—glaucoma	2.45e-05	0.000874	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—OPN4—glaucoma	2.44e-05	0.000871	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—EDN1—glaucoma	2.43e-05	0.000866	CbGpPWpGaD
Atomoxetine—CYP2D6—Biological oxidations—CYP1B1—glaucoma	2.41e-05	0.000861	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—EDN1—glaucoma	2.41e-05	0.00086	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PTGFR—glaucoma	2.4e-05	0.000855	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—OPN4—glaucoma	2.39e-05	0.000852	CbGpPWpGaD
Atomoxetine—CYP2D6—Metapathway biotransformation—CYP1B1—glaucoma	2.38e-05	0.000849	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—NGFR—glaucoma	2.37e-05	0.000847	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—EDN1—glaucoma	2.36e-05	0.000842	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—SMO—glaucoma	2.35e-05	0.00084	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—EDN1—glaucoma	2.35e-05	0.000838	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CA5A—glaucoma	2.31e-05	0.000823	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—NARFL—glaucoma	2.31e-05	0.000823	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HEYL—glaucoma	2.28e-05	0.000816	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—LRP12—glaucoma	2.27e-05	0.000809	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HEYL—glaucoma	2.27e-05	0.000809	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—NTRK1—glaucoma	2.26e-05	0.000805	CbGpPWpGaD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—TNF—glaucoma	2.22e-05	0.000794	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HEYL—glaucoma	2.22e-05	0.000792	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PTGFR—glaucoma	2.21e-05	0.00079	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PTGFR—glaucoma	2.2e-05	0.000784	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PTGFR—glaucoma	2.15e-05	0.000767	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CA5A—glaucoma	2.12e-05	0.000757	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—NARFL—glaucoma	2.12e-05	0.000757	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—C3—glaucoma	2.12e-05	0.000757	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—C3—glaucoma	2.1e-05	0.000751	CbGpPWpGaD
Atomoxetine—CYP2C19—Biological oxidations—GSTM1—glaucoma	2.1e-05	0.000748	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CDKN2B—glaucoma	2.08e-05	0.000742	CbGpPWpGaD
Atomoxetine—CYP2C19—Metapathway biotransformation—GSTM1—glaucoma	2.07e-05	0.000738	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—C3—glaucoma	2.06e-05	0.000735	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	2.05e-05	0.000732	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—EDN1—glaucoma	2.04e-05	0.000727	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—EDN1—glaucoma	1.99e-05	0.000712	CbGpPWpGaD
Atomoxetine—CYP3A4—Biological oxidations—GSTT1—glaucoma	1.98e-05	0.000706	CbGpPWpGaD
Atomoxetine—CYP2D6—Biological oxidations—GSTM1—glaucoma	1.93e-05	0.000688	CbGpPWpGaD
Atomoxetine—CYP2D6—Metapathway biotransformation—GSTM1—glaucoma	1.9e-05	0.000679	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—SMO—glaucoma	1.89e-05	0.000674	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—SMO—glaucoma	1.87e-05	0.000669	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—SMO—glaucoma	1.84e-05	0.000655	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—NGF—glaucoma	1.83e-05	0.000654	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—OPN4—glaucoma	1.81e-05	0.000646	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—EDN1—glaucoma	1.79e-05	0.000638	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	1.78e-05	0.000635	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—C3—glaucoma	1.74e-05	0.000622	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—RPTOR—glaucoma	1.73e-05	0.000618	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—RPTOR—glaucoma	1.72e-05	0.000613	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—RPTOR—glaucoma	1.68e-05	0.000601	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HEYL—glaucoma	1.68e-05	0.000601	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NCK2—glaucoma	1.68e-05	0.000599	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NCK2—glaucoma	1.66e-05	0.000594	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NCK2—glaucoma	1.63e-05	0.000582	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PTGFR—glaucoma	1.63e-05	0.000582	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—APOE—glaucoma	1.62e-05	0.000579	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CAV1—glaucoma	1.61e-05	0.000574	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—TP53—glaucoma	1.6e-05	0.000571	CbGpPWpGaD
Atomoxetine—Pseudoephedrine—TNF—glaucoma	1.6e-05	0.491	CrCbGaD
Atomoxetine—CYP3A4—Biological oxidations—CYP1B1—glaucoma	1.58e-05	0.000563	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—OPN4—glaucoma	1.57e-05	0.000561	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—VEGFA—glaucoma	1.56e-05	0.000557	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—C3—glaucoma	1.56e-05	0.000557	CbGpPWpGaD
Atomoxetine—CYP3A4—Metapathway biotransformation—CYP1B1—glaucoma	1.55e-05	0.000555	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—EDN1—glaucoma	1.55e-05	0.000554	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—FN1—glaucoma	1.53e-05	0.000546	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—BAD—glaucoma	1.51e-05	0.000539	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HEYL—glaucoma	1.46e-05	0.000522	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HDAC9—glaucoma	1.43e-05	0.000509	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PTGFR—glaucoma	1.42e-05	0.000505	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HDAC9—glaucoma	1.42e-05	0.000505	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—SMO—glaucoma	1.39e-05	0.000496	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CA5A—glaucoma	1.39e-05	0.000495	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NARFL—glaucoma	1.39e-05	0.000495	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HDAC9—glaucoma	1.39e-05	0.000495	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—EDN1—glaucoma	1.37e-05	0.000489	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—EDN1—glaucoma	1.36e-05	0.000486	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—C3—glaucoma	1.36e-05	0.000484	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—TNF—glaucoma	1.34e-05	0.000478	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—EDN1—glaucoma	1.33e-05	0.000476	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—RPTOR—glaucoma	1.28e-05	0.000455	CbGpPWpGaD
Atomoxetine—CYP3A4—Biological oxidations—GSTM1—glaucoma	1.26e-05	0.00045	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—EDN1—glaucoma	1.25e-05	0.000444	CbGpPWpGaD
Atomoxetine—CYP3A4—Metapathway biotransformation—GSTM1—glaucoma	1.24e-05	0.000444	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—EDN1—glaucoma	1.24e-05	0.000441	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NCK2—glaucoma	1.23e-05	0.000441	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—NOS3—glaucoma	1.22e-05	0.000434	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—EDN1—glaucoma	1.21e-05	0.000432	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—SMO—glaucoma	1.21e-05	0.000431	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—C3—glaucoma	1.2e-05	0.000428	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—C3—glaucoma	1.19e-05	0.000424	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—C3—glaucoma	1.16e-05	0.000415	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CA1—glaucoma	1.13e-05	0.000402	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SMO—glaucoma	1.12e-05	0.000398	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—RPTOR—glaucoma	1.11e-05	0.000395	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SMO—glaucoma	1.11e-05	0.000395	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CTSA—glaucoma	1.09e-05	0.000389	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—C3—glaucoma	1.09e-05	0.000388	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SMO—glaucoma	1.08e-05	0.000387	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—C3—glaucoma	1.08e-05	0.000385	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NCK2—glaucoma	1.07e-05	0.000383	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—C3—glaucoma	1.06e-05	0.000377	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CDKN1B—glaucoma	1.05e-05	0.000376	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HDAC9—glaucoma	1.05e-05	0.000375	CbGpPWpGaD
Atomoxetine—Fenoprofen—PTGS2—glaucoma	1.04e-05	0.32	CrCbGaD
Atomoxetine—CYP2D6—Metabolism—CA1—glaucoma	1.04e-05	0.00037	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CA2—glaucoma	1.03e-05	0.000368	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NTRK2—glaucoma	1.02e-05	0.000364	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NTRK2—glaucoma	1.01e-05	0.000361	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—EDN1—glaucoma	1.01e-05	0.00036	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	1.01e-05	0.000359	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	1.01e-05	0.000359	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CTSA—glaucoma	1e-05	0.000358	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NTRK2—glaucoma	9.92e-06	0.000354	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—MMP9—glaucoma	9.75e-06	0.000348	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CA2—glaucoma	9.47e-06	0.000338	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—EDN1—glaucoma	9.17e-06	0.000327	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HDAC9—glaucoma	9.12e-06	0.000325	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—C3—glaucoma	8.82e-06	0.000315	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—EDN1—glaucoma	8.77e-06	0.000313	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NGFR—glaucoma	8.76e-06	0.000313	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—VEGFA—glaucoma	8.75e-06	0.000312	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NGFR—glaucoma	8.69e-06	0.00031	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NGFR—glaucoma	8.51e-06	0.000304	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NTRK1—glaucoma	8.32e-06	0.000297	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NTRK1—glaucoma	8.26e-06	0.000295	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SMO—glaucoma	8.22e-06	0.000293	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NTRK1—glaucoma	8.08e-06	0.000289	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—C3—glaucoma	8.01e-06	0.000286	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—EDN1—glaucoma	7.96e-06	0.000284	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CDKN2B—glaucoma	7.67e-06	0.000274	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—C3—glaucoma	7.66e-06	0.000273	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CDKN2B—glaucoma	7.61e-06	0.000272	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NTRK2—glaucoma	7.52e-06	0.000268	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CDKN2B—glaucoma	7.45e-06	0.000266	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—EDN1—glaucoma	7.36e-06	0.000263	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—EDN1—glaucoma	7.3e-06	0.000261	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—TXN—glaucoma	7.26e-06	0.000259	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—EDN1—glaucoma	7.15e-06	0.000255	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SMO—glaucoma	7.14e-06	0.000255	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—C3—glaucoma	6.96e-06	0.000248	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CA1—glaucoma	6.77e-06	0.000242	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NGF—glaucoma	6.76e-06	0.000241	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NGF—glaucoma	6.71e-06	0.000239	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—TXN—glaucoma	6.68e-06	0.000238	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—glaucoma	6.62e-06	0.000236	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TP53—glaucoma	6.61e-06	0.000236	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NGF—glaucoma	6.57e-06	0.000234	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—glaucoma	6.56e-06	0.000234	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CTSA—glaucoma	6.56e-06	0.000234	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NTRK2—glaucoma	6.53e-06	0.000233	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NGFR—glaucoma	6.45e-06	0.00023	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—C3—glaucoma	6.43e-06	0.000229	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—C3—glaucoma	6.38e-06	0.000228	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—C3—glaucoma	6.24e-06	0.000223	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CA2—glaucoma	6.19e-06	0.000221	CbGpPWpGaD
Atomoxetine—Ketoprofen—PTGS2—glaucoma	6.16e-06	0.189	CrCbGaD
Atomoxetine—HTR2C—Signaling Pathways—NTRK1—glaucoma	6.13e-06	0.000219	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—APOE—glaucoma	5.98e-06	0.000214	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—APOE—glaucoma	5.94e-06	0.000212	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CAV1—glaucoma	5.93e-06	0.000212	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CAV1—glaucoma	5.88e-06	0.00021	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—APOE—glaucoma	5.81e-06	0.000208	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CAV1—glaucoma	5.76e-06	0.000206	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CDKN2B—glaucoma	5.65e-06	0.000202	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—FN1—glaucoma	5.64e-06	0.000201	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTT1—glaucoma	5.63e-06	0.000201	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—FN1—glaucoma	5.6e-06	0.0002	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NGFR—glaucoma	5.6e-06	0.0002	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—BAD—glaucoma	5.58e-06	0.000199	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—BAD—glaucoma	5.53e-06	0.000197	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—FN1—glaucoma	5.48e-06	0.000196	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—EDN1—glaucoma	5.42e-06	0.000193	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—BAD—glaucoma	5.42e-06	0.000193	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NTRK1—glaucoma	5.32e-06	0.00019	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTT1—glaucoma	5.18e-06	0.000185	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NGF—glaucoma	4.98e-06	0.000178	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CDKN2B—glaucoma	4.9e-06	0.000175	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—C3—glaucoma	4.73e-06	0.000169	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EDN1—glaucoma	4.7e-06	0.000168	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	4.54e-06	0.000162	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP1B1—glaucoma	4.48e-06	0.00016	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ABCA1—glaucoma	4.48e-06	0.00016	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NOS3—glaucoma	4.48e-06	0.00016	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NOS3—glaucoma	4.45e-06	0.000159	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—APOE—glaucoma	4.41e-06	0.000157	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CAV1—glaucoma	4.37e-06	0.000156	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TXN—glaucoma	4.36e-06	0.000156	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NOS3—glaucoma	4.36e-06	0.000155	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NGF—glaucoma	4.32e-06	0.000154	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—FN1—glaucoma	4.15e-06	0.000148	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP1B1—glaucoma	4.12e-06	0.000147	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ABCA1—glaucoma	4.12e-06	0.000147	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—C3—glaucoma	4.11e-06	0.000147	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—BAD—glaucoma	4.11e-06	0.000147	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CDKN1B—glaucoma	3.88e-06	0.000139	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CDKN1B—glaucoma	3.85e-06	0.000138	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—APOE—glaucoma	3.83e-06	0.000137	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CAV1—glaucoma	3.79e-06	0.000135	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CDKN1B—glaucoma	3.77e-06	0.000135	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—FN1—glaucoma	3.61e-06	0.000129	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MMP9—glaucoma	3.6e-06	0.000128	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTM1—glaucoma	3.58e-06	0.000128	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MMP9—glaucoma	3.57e-06	0.000127	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—BAD—glaucoma	3.57e-06	0.000127	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MMP9—glaucoma	3.49e-06	0.000125	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTT1—glaucoma	3.38e-06	0.000121	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NOS3—glaucoma	3.3e-06	0.000118	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTM1—glaucoma	3.3e-06	0.000118	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—VEGFA—glaucoma	3.23e-06	0.000115	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—VEGFA—glaucoma	3.2e-06	0.000114	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—MTHFR—glaucoma	3.17e-06	0.000113	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—VEGFA—glaucoma	3.14e-06	0.000112	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—APOE—glaucoma	2.95e-06	0.000105	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CAV1—glaucoma	2.92e-06	0.000104	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—MTHFR—glaucoma	2.91e-06	0.000104	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NOS3—glaucoma	2.87e-06	0.000102	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CDKN1B—glaucoma	2.86e-06	0.000102	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—APOE—glaucoma	2.71e-06	9.68e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ABCA1—glaucoma	2.7e-06	9.62e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP1B1—glaucoma	2.7e-06	9.62e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CAV1—glaucoma	2.69e-06	9.59e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MMP9—glaucoma	2.65e-06	9.45e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CDKN1B—glaucoma	2.48e-06	8.86e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TP53—glaucoma	2.44e-06	8.71e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TP53—glaucoma	2.42e-06	8.64e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—VEGFA—glaucoma	2.38e-06	8.49e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TP53—glaucoma	2.37e-06	8.46e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MMP9—glaucoma	2.3e-06	8.21e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—NOS3—glaucoma	2.21e-06	7.89e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTM1—glaucoma	2.16e-06	7.69e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—VEGFA—glaucoma	2.07e-06	7.37e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—NOS3—glaucoma	2.03e-06	7.25e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTGS2—glaucoma	2.02e-06	7.21e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—MTHFR—glaucoma	1.9e-06	6.8e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTGS2—glaucoma	1.86e-06	6.63e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TP53—glaucoma	1.8e-06	6.41e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—APOE—glaucoma	1.77e-06	6.33e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CAV1—glaucoma	1.76e-06	6.27e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TP53—glaucoma	1.56e-06	5.57e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NOS3—glaucoma	1.33e-06	4.74e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTGS2—glaucoma	1.22e-06	4.34e-05	CbGpPWpGaD
